{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266933","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.529026+00:00","generated_at":"2026-05-17T00:22:35.716108+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M","bullets":["DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.","Ex-US regulatory clearance obtained; Phase 1 MAD trial in Australia to start H1 2026; splicing data expected 2027.","Q3 2025 net loss $17.0M; R&D expense $14.6M; G&A expense $4.7M.","Cash and securities $206.0M as of Sept 30, 2025, supporting pipeline advancement.","Board appointed Justin Gover (former CEO of GW Pharma, led $7B acquisition by Jazz) in September 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266933","json":"https://secwatch.observer/filing/0001193125-25-266933.json","markdown":"https://secwatch.observer/filing/0001193125-25-266933.md","text":"https://secwatch.observer/filing/0001193125-25-266933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/0001193125-25-266933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/dsgn-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:22:35.716108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}